NEW YORK, NY / ACCESSWIRE / May 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI). Investors who purchased Treace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMCI.
Investigation Details:
On May 7, 2024, Treace issued a press release reporting its financial results for the first quarter of 2024. Among other items, Treace issued a "revise[d] guidance range for full-year 2024, expecting revenues of $201 million to $211 million from $220 million to $225 million[.]" Explaining the revised guidance, Treace's Chief Executive Officer cited "increased use of MIS Osteotomy solutions and more competition from knockoffs of our Lapiplasty® products." J.P. Morgan subsequently downgraded Treace, citing the revised guidance and noting that it lacks clarity over how much market share Treace can reclaim as it competes against larger orthopedic peers. On this news, Treace's stock price fell $6.95 per share, or 62.5%, to close at $4.17 per share on May 8, 2024.
What's Next?
If you are aware of any facts relating to this investigation or purchased Treace securities, you can assist this investigation by visiting the firm's site: bgandg.com/TMCI. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller,
332-239-2660 | [email protected]
SOURCE: Bronstein, Gewirtz and Grossman, LLC